【正文】 and not intended for physicians from France, Japan or the United States. 169。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 25 COMPARE研究 : 隨訪 3 年支架血栓發(fā)生率 COMPARE: 支架血栓 – 3年 (ARC 確定的 ) 單中心 , 1,800例患者 ISS研究， 1:1 隨機入組 XIENCE (n=897) vs. Taxus Liberte (n=903) Source: Smits, P. Compare 3 Year Results. TCT 2020 p= (logrank test) 69% 累計事件發(fā)生率 術后時間（天） Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 26 XIENCE: 與 Cypher相比持續(xù)的低支架血栓發(fā)生率 0 . 10 . 70 . 3 20 . 3 80 . 61 . 40 . 51 . 6確定的支架血栓發(fā)生率 (%)XIENCE V n=1390 Cypher n=1384 XIENCE V n=1597 Cypher n=1600 XIENCE V n=652 Cypher n=652 XIENCE V n=1342 Cypher n=1342 p= plogrank= p= p= % % % % % % % % SORTOUT IV1 9 months ISARTEST 43 2 year LESSON 14 3 year RESET2 1 year ARC definite stent thrombosis is confirmed by the presence of an acute coronary syndrome with angiographic or autopsy evidence of thrombus or occlusion. Results from different clinical trials are not directly parable. Information provided for educational purposes only. Sources: 1L. Okkels Jensen, SORT OUT IV 9Month Results Presentation. TCT 2020. ST rates are from KaplanMeier estimates. 2T. Kimura, RESET 1Year Results Presentation. ESC 2020. ST rates are from KaplanMeier estimates. 3R. Byrne. ISAR Test 4 2Year Results Presentation. TCT 2020. 4L. Raber, et al. LongTerm Comparison of EverolimusEluting and SirolimusEluting Stents for Coronary Revascularization. JACC Vol. 57, No. 21, 2020:2143– 51. Investigator Sponsored Study Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 27 RESOLUTE All Comers 研究 3年 結 果 ? 由美敦力 資 助的獨立的無 篩選 患者研究 ? 2,292 名患者 1:1 入 組 XIENCE V及 Resolute ? 比 較 XIENCE 與 Resolute最大的RCT研究 Source: Windecker S, PCR 2020 雙 聯(lián) 抗血小板治 療 1年 3年 XIENCE V % % Endeavor Resolute % % Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 28 RESOLUTE All Comers 3年 結 果 XIENCE 術 后 3年的支架血栓是 Resolute的一半 ? 1 年確定的支架血栓 發(fā) 生率 : % XIENCE。 % Endeavor Resolute。 p= ? 2 年確定的支架血栓 發(fā) 生率 : % XIENCE。 % Endeavor Resolute。 p= % % p= XIENCE V n=1,130 Endeavor Resolute n=1,120 3 年確定的支架血栓 發(fā) 生率 支架血栓 (%) Source: 3 year data: Windecker S, PCR 2020, 1 and 2 year data: Silber S, et al. Unrestricted randomized use of two new generation drugeluting coronary stents: 2year patientrelated versus stentrelated outes from the RESOLUTE All Comers trial. The Lancet. April 9, 2020。377:124147. Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 30 EXAMINATION 研究 XIENCE的安全性優(yōu)于 BMS ? 由研究者獨立進行的隨機研究， 1,498名 STEMI患者， 1:1隨機入組 XIENCE V 及 MULTILINK VISION ? 主要終點 : ARC 定義患者導向的 1年復合終點，包括全因死亡，全因心梗，全部血運重建 ? 1年隨訪率 98% Source: M. Sabate, EXAMINATION 1Year Presentation. ESC 2020. Investigator Sponsored Study 患者導向復合終點 XIENCE V MULTILINK VISION p值 % % 支架相關終點 終點 XIENCE V MULTILINK VISION p值 TLR % % TVR % % 無篩選 STEMI患者 n=1,498 XIENCE V n=741 MULTILINK VISION n=747 “在臨床表現(xiàn)上， Xience V支架顯著降低TVR和 TLR的發(fā)生率，以及確定的 /可能的支架血栓發(fā)生率 .” Dr. Manel Sabate Principal Investigator, EXAMINATION Trial Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。2020